Hemab Therapeutics Holdings, Inc.
COAGDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 20, 2026
16dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
Sutacimig
Congenital Factor VII Deficiency
HMB-002 (Part A)
Von Willebrand Disease (VWD)
HMB-001
Glanzmann Thrombasthenia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Sutacimig | Phase 2 | Congenital Factor VII Deficiency | - | - |
HMB-002 (Part A) | Phase 2 | Von Willebrand Disease (VWD) | - | - |
HMB-001 | Phase 2 | Glanzmann Thrombasthenia | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Hemab Therapeutics Holdings, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Hemab Therapeutics Holdings, Inc.'s (COAG) pipeline across Phase 2. Its lead program is Sutacimig (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Hemab Therapeutics Holdings, Inc.'s next FDA catalyst?→
Hemab Therapeutics Holdings, Inc.'s (COAG) next tracked catalyst is a Earnings expected August 20, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track COAG biotech catalysts?→
Add COAG to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Hemab Therapeutics Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.